Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και Εκτέλεση
Library of the School of Health Sciences

2021-02-27

2021

Pappa Christianna

1. Κίμων Σταματελόπουλος, Αναπληρωτής Καθηγητής, Iατρική Σχολή, ΕΚΠΑ
2. Ευάγγελος Τέρπος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
3. Μαρία Γαβριατοπούλου, Επίκουρη Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ

Η δράση των β-αναστολέων στην καρδιακή ανεπάρκεια

Greek

Beta Blockers in heart failure

Heart failure is a disease with high mortality and significant economic consequences for health systems worldwide. It results in dysfunction and remodeling of the left ventricle of the heart leading to progressive worsening of patient symptoms and eventually death.
Beta-blockers are a class of drugs that reduce the action of the sympathetic nervous system, by competevly blocking the β-receptors where catecholamines act. They are used in the treatment of cardiac arrhythmias, acute myocardial infarction, hypertension and in recent years and in the treatment of patients with heart failure, despite the initial contraindication they had for this condition.
This paper is intended to investigate the effect of the use of β-blockers in patients with chronic heart failure and to find possible new therapeutic targets for groups of patients that have not been thoroughly investigated. For this purpose, the literature of large randomized clinical trials and meta-analyzes was investigated.
Metoprolol along with bisoprolol and carvedilol are the most commonly used beta-blockers in patients with heart failure. The fact that these patients often have specific characteristics, such as gender, race, advanced age, or comorbidities such as atrial fibrillation, diabetes, etc., makes it necessary to further investigate their effect on these groups of patients.

Health Sciences

Heart failure, Beta-Blockers, Randomized Clinical Trials, Subgroups

No

0

No

56

51

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/2937260